Invokana Sales Figure Witness a Dip
Invokana Sales Figure Witness a Dip
Introduction
According to the fourth quarter 2017 sales earnings report released by J&J, Invokana made $262 million which was a 29% dip when compared to the previous reports. The low figures are reasoned to be due to the growing competition and awareness of the side-effects associated with this the Type 2 diabetes medication.
Comments
Latest News
Court Approves $700M Opioid Settlement for Acute Hospitals
Categories: Opioids
A federal court has approved a $700 million class-action settlement that will compensate over 1,000 acute care hospitals for costs related to the opioid crisis.
The settlement consolidates four separate agreements involving major drug…
Philips Settles CPAP Lawsuits Over Toxic Foam for $1.1B
Categories: Philips CPAP/BiPAP/ASV Sleep Apnea Machines
Philips has been embroiled in legal battles following the recall of millions of CPAP, BiPAP, and ventilator devices due to toxic foam degradation.
The breakdown of the foam in these machines may release harmful chemicals, raising serious…
Texas Trial to Decide J&J’s $10B Talcum Powder Settlement
Categories: Talcum
A high-stakes trial in Texas will determine whether Johnson & Johnson (J&J) can resolve tens of thousands of talcum powder cancer lawsuits through a…